Long Term Survival in Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents-Reference-Cited by-同舟云学术

Long Term Survival in Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents

Published:2021-12 Issue:2 Volume:1 Page:41-54
ISSN:2784-0131
Container-title:Journal of Medical and Radiation Oncology
language:
Short-container-title:JMRO

Author:

Paul Doru¹,Rybstein Marrisa²

Affiliation:

1. Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York

2. Division of Hematology-Oncology, Department of Medicine, NYU Long Island School of Medicine

Abstract

"Background: Several studies have shown that tyrosine kinase inhibitors (TKI) and chemotherapy improve the short term and median survival of patients with metastatic adenocarcinoma of the lung (MAL), but there is less data on the long-term survival (LTS) of these patients. Methods: A univariate retrospective analysis was performed on 174 patients with MAL diagnosed at our institution between 2009 and 2011, and with up to a 5-year follow-up. Overall survival was estimated using the product-limit method and drawing the Kaplan-Meier curves and compared using the log-rank test. Results: Factors associated with a statistically significant survival benefit in our patients were: having undergone lung surgery, female gender, never smokers, bronchioalveolar histology, and lower TNM nodal stage. Particularly prior lung surgery was shown to improve survival in patients treated with erlotinib. This was also true when comparing patients from a historical cohort as well. Among patients with EGFR mutation, there was no statistically significant difference in survival amongst patients treated with either surgery or erlotinib. Conclusion: In our patients with MAL the only treatment modality that improved LTS in a statistically significant way was lung surgery. This is an important finding as NCCN guidelines consider surgery as a treatment option only in MAL with isolated lesions."

Publisher

Asociatia Societatea Transdisciplinara de Oncologie Personalizata Pentru Combaterea Cancerului - Stop Cancer

Reference25 articles.

1. "1. Lung and Bronchus Cancer - Cancer Stat Facts [Internet]. [cited 2019 Feb 10]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html

2. 2. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010 Mar;2(1):48–51.

3. 3. Da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69.

4. 4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123–132.

5. 5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239–246.